Celtic Biotech has a strong management team with expertise in bringing drug candidates from the lab through both pre-clinical and clinical through to the market. Strongly experienced in connecting researchers with the medical community and industry. These skills are essential for successful product development. The management team also has experience in dealing with EU and US medical regulatory systems, the EMA and FDA as well as national authorities. Our team consists of experienced and passionate professionals who have expertise in snake venom research, drug development, clinical trials, regulatory affairs, and marketing. We also collaborate with world-renowned experts and advisors in the fields of oncology, pharmacology, and anti-aging.
Dr. Paul F. Reid is the CEO, Director and one of the co-founders of Celtic Biotech. He has a PhD in Neurobiochemistry from Imperial College, London, and BA in Microbiology from Trinity College, Dublin. He is a world-renowned expert in the therapeutic use of snake venom neurotoxins. He was formerly the manager of Receptopharm Inc., a Florida-based company specialising in therapeutic venom technologies. Paul is highly experienced in drug production, new drug development, clinical trial design, and experimental design, and is currently based in Florida.
John Reid M.Sc. is COO, Director and co-founder of Celtic Biotech and has a master's degree in international business management from Trinity College, Dublin. He was responsible for securing initial seed capital and developing R&D and consultancy agreements. He also coordinated the start-up activities of early funding and angel investments, information dissemination, and liaison with legal, financial, medical, and scientific advisors in Ireland, Europe & the USA. He is based in Ireland where the Company is incorporated.
Dr. Dorothy Bray is a Senior Executive and Entrepreneur in the biopharmaceutical industry with over 25 years of experience in healthcare management. She is an inventor of multiple patents. Dr. Bray works with a number of healthcare, biotechnology, and nutraceutical companies helping to develop the commercial and clinical development strategy. In the past, she served as a Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline and also as Senior Medical Strategy Head, International Medical Affairs, Glaxo Wellcome Inc, USA and as Principal Clinical Research Scientist at Antivirals, Glaxo Wellcome, UK, and the USA. Dr. Bray has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non-government organizations in key developed and emerging markets. She is the European Commission's Scientific Expert and acts as a business advisor to investment companies in the USA and Europe.
Dr. François-Michel Delgado MD, is Consultant physician/Medical Oncologist, Service d’Oncologie Medicale Groupe Hospitalier Pitie Salpétrière 47-83 Boulevard de l’Hôpital 75013 Paris. Dr Delgado was previously Head of Clinical Development at the Oncology Department Rhône-Poulenc, Paris between 1986- 1988. He then took up the position of Medical Director at the Institut de Recherche Pierre Fabre, Boulogne-Billancourt- France later becoming Director of Clinical Development at the Medicament Oncology Department (PFO) Boulogne-Billancourt there from 1998 to 2011. Dr Delgado has also worked alongside Prof. David Khayat as Consultant physician at the Oncology Service at the University Hospital Pitié Salpétrière since 1998. Dr Delgado had also been involved in Post Graduate Training for Clinical Oncology at the MD Anderson Cancer Center Houston USA and is a member of the European Society of Medical Oncology (ESMO) and the American Society of Medical Oncology (ASCO). Dr Delgado presented the results of Celtic Biotech sponsored Phase I Clinical Studies Parts 1 & 2 at the American Association of Cancer Research (AACR) annual conference in April 2018.
Prof. Zheng Hong Qin, MD, Ph.D. is a professor of pharmacology at the Department of pharmacology in the school of pharmacy of Suzhou University. He received his Ph.D. in pharmacology from Pennsylvania Medical College in 1994. He did his postdoctoral work at the National Institutes of health in the US and later lectured at Harvard University. He is Deputy director of anti-aging Academic Committee of Chinese society of Gerontology and geriatrics, member of biochemical and Molecular Pharmacology Professional Committee, member of neuro and psychopharmacology professional committee, and editorial board member of Chinese Journal of pharmacology. He was selected as China’s most highly cited scholar for five consecutive years in 2014-2018. He is chief scientific collaborator on the development of Celtic Biotech company IP and has been overseeing R&D on behalf of the Company. He has co-authored several papers with Dr. Reid on the mechanism of action of CB-24 and its toxicity against several cancer cell lines, as well as studies on the analgesic properties of the drug.
Prof. John Crown MD is an Irish consultant oncologist and former politician. His postdoctoral training took place at Guy's Hospital in London and St. James's Hospital in Dublin. He completed his training in oncology in New York at Mount Sinai Medical Center and the Memorial Sloan–Kettering Cancer Center. He held the post of assistant professor at Weill Cornell Medical College of Cornell University until 1993 when he returned to Ireland, becoming a consultant at two Dublin hospitals: St. Vincent's and St. Luke's. He holds professorships in cancer research from Dublin City University and University College Dublin. Crown has worked to reform cancer treatment in Ireland as chairman of molecular therapeutics for Cancer Ireland, and founder of the Ireland Co-operative Oncology Research Group (ICORG). Prof. Crown became a Member of the Royal Irish Academy on 2021.
Dr. Margit Jeschke is currently an independent consultant based in Switzerland. She joined the Scientific Advisory board of Celtic Biotech in 2023. Margit was previously Novartis Global Head of Analytical Stewardship & CMC Correlational Sciences from Sept 2016 - Dec 2021 and her remit also included responsibility for the analytical development strategy of the company’s Cell & Gene Therapy products and analytical chapters of CAR T product regulatory filings. Before this she held the position of Global Head Analytical Development for Cell and Gene Therapy including managing an international team of Analytical Development associates located in the US and Europe. One of Margits key achievements was the BLA approval of KymriahTM , MAA, submitted in Nov 2017 (under orphan designation and with Break Through Therapy and Prime designation). Margit was also onetime Executive Director Novartis Analytical R&D Biologics where she was responsible for all aspects of analytical development and product release of drug substance and finished product for clinical development involving 40+ projects up to BLA/MMA approval including the successful global filing of several Biologics products.
Dr. Maria Angeles Gil-Delgado MD, Consultant Medical Oncologist, Pitié-Salpetriere Hospital, Paris. Previously Head of Clinic at the Oncology Institute of San Sebastian (Spain) and Head of Medical Oncology Department at the Internal Medecine Section of Granada University Hospital. Dr. Gil-Delgado was one time Researcher in charge of the Clinical Trial Bureau of the Institute of Oncology and Immunogenetics, and at the University Hospital Paul Brousse (Pr. J.L. Misset) for Phase I, II, III clinical trials: She was involved in the research and evaluation of such new drugs as; mitoxantrone, vinorelbine, THP doxorubicin, fludarabine, pentasosin, vinflunine (Phase I), cetuximab etc. She is currently Senior Assistant in the Medical Oncology Department at the University Hospital Pité Salpétrière-Paris-France where she has worked with Professor David Khayat. Dr. Gil-Delgado is an active member of the European Society of Medical Oncology and the American Society of Medical Oncology. Dr. Gil-Delgado oversaw the Celtic Biotech Phase I Part 2 clinical trials